Search Results
Your search for The matches 34659 pages
Showing 28351 - 28400Maintenance Treatment With Capecitabine and Bevacizumab Is Effective in Metastatic Colorectal Cancer
In patients with metastatic colorectal cancer, maintenance treatment with capecitabine plus bevacizumab (Avastin) after induction treatment with capecitabine, oxaliplatin, and bevacizumab (CAPOX-B) significantly delayed disease progression, compared to observation, according to the final results of ...
Expert Point of View: Manish Shah, MD
Manish Shah, MD, Director of Gastrointestinal Oncology and Associate Professor of Medicine at New York–Presbyterian/Weill Cornell Medical Center in New York, discussed the findings of the RAINBOW trial at the 2014 Gastrointestinal Cancers Symposium. Dr. Shah noted that in this “well sized” study,...
Ramucirumab Plus Paclitaxel Improves Overall Survival After First Progression in Metastatic Gastric Cancer
In the global phase III RAINBOW trial in patients with metastatic gastric cancer, the investigational monoclonal antibody ramucirumab significantly improved both progression-free and overall survival, when added to paclitaxel in second-line therapy, as reported at the 2014 Gastrointestinal Cancers...
Jamie H. Von Roenn, MD, and ASCO: A Perfect Fit
Dr. Von Roenn’s history with ASCO spans nearly 3 decades. She has served on ASCO’s Board of Directors, the ASCO Palliative Care Task Force, the Scientific Program, Cancer Education, and Cancer Communications Committees, among others. In 2011, Dr. Von Roenn received the ASCO-ACS Award at the Annual...
ASCO's Education and Professional Development Services
Last September, Jamie H. Von Roenn, MD, left her position as Professor of Medicine at the Northwestern University Feinberg School of Medicine in Chicago to join ASCO as its Senior Director of Education, Science and Professional Development. In her new position, Dr. Von Roenn will provide strategic...
Paving the Way for the Surgeon General’s Report
The connection between smoking and lung cancer is universally accepted as scientific fact, and those who choose to smoke are painfully aware of the risk it poses for addiction and subsequent cancer. However, to fully appreciate the significance of the Surgeon General’s report, one must turn back to ...
Perspective on the Politics of Tobacco
The tobacco industry has always been a major player in congressional races, especially in Southern tobacco-growing states. Moreover, the industry is notoriously bipartisan in their political donations, and members of both parties have returned the favor by voting for tobacco interests. “The 2014...
Highlights of the American Lung Association’s State of Tobacco Control 2014
A state-by-state update on the progress of antismoking initiatives. States are graded on four metrics: tobacco prevention, smoke-free air, cigarette tax, and cessation coverage. For example, Kentucky received 4 F’s, while New York received grades of, F, A, A, and F, respectively. Major parts of the ...
The Surgeon General’s Report on Tobacco Turns 50: Much Success, Much Work Ahead
On January 11, 2014, the nation commemorated the 50th anniversary of a document that transformed our public health landscape and has saved millions of lives: Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service. This groundbreaking report, which...
Expert Point of View: Rebecca Miksad, MD, MPH
Rebecca Miksad, MD, MPH, Assistant Professor of Medicine at Harvard Medical School and Attending Physician, Gastrointestinal Medical Oncology, Beth Israel Deaconess Medical Center, Boston, discussed the findings at the symposium and the potential for immunotherapy in pancreatic cancer....
Immunotherapy Duo Improves Survival in Metastatic Pancreatic Cancer
Overall survival was improved in metastatic pancreatic cancer patients through an innovative immunotherapy strategy in a multicenter study reported at the 2014 Gastrointestinal Cancers Symposium.1 “This is the first time a randomized study has shown that immunotherapy is effective in pancreatic...
R-GCVP Regimen for Patients With Diffuse Large B-Cell Lymphoma and Cardiac Comorbidity
For patients with diffuse large B-cell lymphoma (DLBCL) who are unable to receive anthracycline-containing chemoimmunotherapy because of cardiac comorbidity, a regimen of rituximab (Rituxan), gemcitabine, cyclophosphamide, vincristine, and prednisolone (R-GCVP) “is an active, reasonably...
Nintedanib Combined With Docetaxel Is Effective Second-Line Option for Advanced NSCLC
The combination of nintedanib and docetaxel “is an effective second-line option” for patients with advanced non–small cell lung cancer (NSCLC) who have received previous treatment with one line of platinum-based therapy, according to results from the phase III LUME-Lung 1 study published in The...
About City of Hope
City of Hope was founded in 1913, but its focus on cancer research and care began in the late 1940s. The center has performed 11,000 hematopoietic stem cell transplants as of 2012 with patient outcomes that consistently exceed national averages. City of Hope received its NCI designation as a...
City of Hope’s New Chief Scientific Officer and Cancer Center Director Reflects on His Career Path and the Future of Cancer Care
City of Hope in Duarte, California, has named Steven T. Rosen, MD, as its first Provost and Chief Scientific Officer. Dr. Rosen will guide the scientific direction of the center’s medical research, treatment, and education. He will also assume directorship of the comprehensive cancer institute,...
David A. Fullerton, MD, Named President of The Society of Thoracic Surgeons
David A. Fullerton, MD, of the University of Colorado School of Medicine, was elected President of The Society of Thoracic Surgeons (STS) at the Society’s 50th Annual Meeting in Orlando, Florida. “STS has been a preeminent medical society for many years,” said Dr. Fullerton. “It is truly a great...
Cancer Treatment Centers Names Sr. Vice President, Patient Care Services
Cancer Treatment Centers of America in Philadelphia has announced they have recently hired Nancy G. Hesse, MSN, RN, as the hospital’s Senior Vice President of Patient Care Services. In her new role, Ms. Hesse will work on several key initiatives for her team related to engagement, communication,...
Dana-Farber Receives $900,000 Grant to Research Ovarian Cancer
The Ovarian Cancer Research Foundation has awarded researchers at Dana-Farber Cancer Institute a $900,000 grant to test new combinations of targeted drugs against the disease. Ursula Matulonis, MD, Director of the Gynecological Cancer Treatment Center in the Susan F. Smith Center for Women’s...
President’s Cancer Panel Issues Urgent Call to Action for HPV Vaccination
Achieving widespread human papillomavirus (HPV) vaccination is one of the most profound opportunities for cancer prevention, according to a report recently released by the President’s Cancer Panel. The Panel’s report, Accelerating HPV Vaccine Uptake: Urgency for Action to Prevent Cancer, issues an ...
Advanced Practitioner Society for Hematology and Oncology (APSHO) Welcoming Members
The Advanced Practitioner Society for Hematology and Oncology (APSHO) is issuing a call for members to oncology nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, and pharmacists. The Society was launched recently during JADPRO Live, a meeting of the...
Cancer Pain: The Humbling Reality
As a medical oncologist and palliative care physician, I’ve had the privilege of caring for cancer patients and delivering primary palliative care and symptom control, as well as the chance to care for patients especially referred for complex pain and symptom problems (in secondary and even...
Short-Term Follow-Up Reveals Suboptimal Pain Relief and Marked Pain Worsening in Ambulatory Patients With Cancer
In an analysis reported in the Journal of Clinical Oncology, Fengmin Zhao, MS, PhD, Dana-Farber Cancer Institute, Boston, and colleagues assessed factors associated with pain severity changes in ambulatory patients with invasive solid tumors (breast, prostate, colon/rectum, or lung) in the Eastern...
Overdiagnosis of Breast Cancer: New Research Directions
Currently, one of the most challenging problems in oncology is to accurately predict whether neoplastic lesions detected by screening tests will progress. The focus on developing ever-more sensitive cancer screening tests has produced the clinical dilemma of overdiagnosis. Overdiagnosis occurs when ...
The Canadian National Breast Screening Trial Had So Many Flaws That Its Results Should Not Be Used to Guide Screening Recommendations
If a randomized, controlled trial of therapy for breast cancer was submitted for publication in which 1. The drug being tested was old and ineffective, and 2. prior to randomization, the women underwent a clinical breast examination and the study coordinators knew who had the largest cancers, and...
Flaws in CNBSS Are Vast, Impact on Screening Recommendations Is Nil
The recent report from the Canadian National Breast Screening Study (CNBSS)—published in BMJ and reviewed in The ASCO Post, early release online—concluded that annual mammography in women aged 40 to 59 does not result in a reduction in mortality from breast cancer beyond that of physical...
No Mortality Benefit of Breast Cancer Mammography Screening in 25-Year Follow-up of Canadian National Breast Screening Study
As reported in BMJ by Anthony B. Miller, MD, Professor Emeritus at the Dalla Lana School of Public Health, University of Toronto, and colleagues, the 25-year follow-up of the Canadian National Breast Screening Study has shown no mortality benefit of annual mammography screening for breast cancer...
2014 Oncology Meetings
MARCH 31st Annual Miami Breast Cancer Conference®March 6-9 • Miami Beach, FloridaFor more information: www.gotoper.com/conferences/mbcc/meetings/31st-Annual-Miami-Breast-Cancer-Conference Hematology and Medical Oncology Board Review: Contemporary Practice from Memorial Sloan-Kettering Cancer...
APSHO: New Society for Advanced Practitioners
The Advanced Practitioner Society for Hematology and Oncology (APSHO) was launched during JADPRO Live. The Society is focused on meeting the unique educational and professional needs of this group of health-care professionals (nurse practioners, physician assistants, clinical nurse specialists,...
Leaders of ASCO, ASH, ASTRO, and NCCN Embrace Collaboration With Advanced Practitioners
Nearly 250 advanced practitioners assembled at the first annual JADPRO Live educational symposium in St. Petersburg, Florida, hosted by the Journal of the Advanced Practitioner in Oncology (JADPRO). Leaders from four prominent oncology organizations championed collaborative practice as not only...
Expert Point of View: Jennifer R. Brown, MD, PhD
Commenting on the CLL 11 trial in chronic lymphocytic leukemia (CLL), Jennifer R. Brown, MD, PhD, Director of the CLL Center at Dana-Farber Cancer Institute, Boston, said she agreed with first author Valentin Goede, MD, that in this study, replacing rituximab (Rituxan) with obinutuzumab (Gazyva) in ...
Encouraging Early Results With Novel Agents in CLL
Two novel agents have shown promising activity in chronic lymphocytic leukemia (CLL), including poor-risk patients: the Bcl-2 inhibitor ABT-199 and the small-molecule PI3K inhibitor IPI-145. Both drugs achieved excellent response rates in heavily pretreated relapsed/refractory patients including...
First-Line Obinutuzumab/Chlorambucil Improves Outcomes Over Rituximab/Chlorambucil in Older CLL Patients With Comorbidities
Obinutuzumab (Gazyva) plus chloramubucil outperformed rituximab (Rituxan) plus chlorambucil (Leukeran) as first-line therapy in older patients with chronic lymphocytic leukemia (CLL) and comorbidities in the large CLL 11 trial. Final results showed that obinutuzumab/chloramubucil improved overall...
FDA Approves Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia
The U.S. Food and Drug Administration (FDA) has expanded the approved use of ibrutinib (Imbruvica) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one previous therapy. Ibrutinib, an oral Bruton’s tyrosine kinase inhibitor, was previously granted...
Expert Point of View: Jeffrey Miller, MD
Jeffrey Miller, MD, Professor of Medicine at the University of Minnesota and Deputy Director of the Masonic Cancer Clinic in Minneapolis, commented on the haploidentical hematopoietic stem cell transplantation studies presented at the American Society of Hematology meeting for The ASCO Post “The...
Haploidentical Stem Cell Transplantation Producing Good Outcomes, Expanding Transplant Pool
HLA-haploidentical hematopoietic stem cell transplantation can be performed safely, yield good outcomes, and greatly expand the number of patients with hematologic malignancies who can be treated with stem cell transplant, studies presented at the 2013 American Society of Hematology (ASH) Annual...
Expert Point of View: C. Kent Osborne, MD
At the San Antonio Breast Cancer Symposium, press briefing moderator C. Kent Osborne, MD, Director of the Dan Duncan Cancer Center at Baylor College of Medicine, Houston, predicted the findings of the study by Badwe et al could be practice-changing. “This is not to say that we shouldn’t perform...
In Stage IV Breast Cancer, the Primary May Not Need to Be Removed
Mastectomy is unnecessary in many women with stage IV breast cancer, according to a study from Indian investigators, reported at the 2013 San Antonio Breast Cancer Symposium.1 The study randomly assigned 350 patients with metastatic breast cancer to mastectomy, complete axillary dissection, plus...
Updated Information on Clinical Trials
Your patients can learn about clinical trials in a variety of ways at www.cancer.net/clinicaltrials. The articles available explain what clinical trials are, how they are used to learn more about cancer care, and how they are conducted. In addition, your patients can read a new article explaining...
Cancer.Net Expands Its Social Media Presence With Launch of Blog
In an effort to continue to bring patients and those who care about and for them the most timely, comprehensive cancer information, ASCO’s patient education website, Cancer.Net, has added a new interactive resource—the Cancer.Net Blog (www.cancer.net/blog). “We decided that a blog made sense for...
Cancer Progress in Jeopardy: Stories From the Front Lines
ASCO is exploring what is happening on the front lines in the laboratory and the clinic due to the shrinking federal funding for cancer research and clinical trials with a series of stories about oncologists. The series is posted on ASCO.org (www.asco.org/nihfunding). In the first article, Robert...
ASCO to Release Report on the State of Cancer Care in America
ASCO is committed to ensuring that Americans have access to high-quality, high-value cancer prevention and treatment services—and that all patients benefit fully from our nation’s investments in cancer research. In mid-March, the Society will be releasing The State of Cancer Care in America: 2014,...
Connecting to Conquer Cancer
Do you share our passion to conquer cancer? Connect with the Conquer Cancer Foundation online to receive up-to-the-minute news and events, researcher spotlights, videos, and updates on progress against cancer worldwide. Visit our website to learn more about our mission and the programs we support:...
Amplifying the Signal: Foundation Donor Takes His Advocacy Into the Twittersphere
Michael A. Thompson, MD, PhD, a Medical Oncologist for Aurora Cancer Care and the Medical Director of Early Cancer Research at Aurora Health Care in Wisconsin, has become something of an expert on the Conquer Cancer Foundation. It began in 2006, when he received a Conquer Cancer Foundation of ASCO...
Expert Point of View: Carlos L. Arteaga, MD
Commenting on the results of the HOPE Study presented at the 2013 San Antonio Breast Cancer Symposium, Carlos L. Arteaga, MD, said, “We all know that this is the right thing to do. This important study provides us with new guidelines and a structure so that patients find it easier to follow the...
Exercise Program Reduces Aromatase Inhibitor–Associated Joint Pain
Amid studies of novel targeted therapies, genetic analyses of tumors, and new ways to approach the treatment of breast cancer, a low-tech study presented at the 2013 San Antonio Breast Cancer Symposium found that a yearlong exercise program reduced joint pain associated with aromatase inhibitors in ...
Innovative I-SPY 2 Trial Yields First Results in Triple-Negative Breast Cancer
An innovative approach to streamlining the testing of novel agents in breast cancer has yielded some of its first results, which were reported at the 2013 San Antonio Breast Cancer Symposium.1 Adaptive Trial Design The veliparib/carboplatin plus standard neoadjuvant therapy regimen is currently...
Expert Point of View: Debu Tripathy, MD
Debu Tripathy, MD, Professor of Medicine, Co-Leader of the Women’s Cancer Program, and the Priscilla and Art Ulene Chair in Women’s Cancer at the University of Southern California Norris Cancer Center, Los Angeles, commented on the APT study for The ASCO Post. “In treating early-stage HER2-positive ...
HER2-Positive Breast Cancer Patients With Small Tumors Benefit From Low-Toxicity Regimen
There may be a benefit for treating small HER2-positive tumors—a breast cancer subset for whom treatment recommendations have not been established but for whom there is still risk of recurrence—and this can be done with little toxicity, according to a multicenter study presented at the 2013 San...
ASCO Applauds CVS Caremark’s Move to Stop Selling Tobacco
CVS Caremark recently announced that it will stop selling cigarettes and other tobacco products at its more than 7,600 CVS/pharmacy stores across the United States by October 1, 2014, making CVS/pharmacy the first national pharmacy chain to take this step in support of the health and well-being of...
GI Symposium Presentations Include Important Updates in Treatment and Prognosis of Pancreatic and Colorectal Cancers
More than 650 studies were presented at the 2014 Gastrointestinal Cancers Symposium, which attracted a multidisciplinary group of more than 3,500 medical, surgical, and radiation oncologists and gastroenterologists. The following briefs highlight a handful of noteworthy studies from the meeting....
